Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Elzovantinib |
Synonyms | |
Therapy Description |
TPX-0022 inhibits Met, Csf1r, and Src, which may lead to growth inhibition in tumor cells (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Elzovantinib | TPX0022|TPX 0022|TPX-0022 | CSF1R Inhibitor 28 MET Inhibitor 59 SRC Inhibitor 31 | Elzovantinib inhibits Met, Csf1r, and Src, which may lead to growth inhibition in tumor cells (PMID: 38564707, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03993873 | Phase Ib/II | Elzovantinib | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) | Active, not recruiting | USA | FRA | ESP | 1 |